![Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-021-00352-3/MediaObjects/41523_2021_352_Fig4_HTML.png)
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
![Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease - Zerdes - 2020 - Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease - Zerdes - 2020 -](https://febs.onlinelibrary.wiley.com/cms/asset/e9ec5994-dcda-4efd-ba36-eda88545f954/mol212654-toc-0001-m.jpg)
Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease - Zerdes - 2020 -
![Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-021-00352-3/MediaObjects/41523_2021_352_Fig1_HTML.png)
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer
![Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology](https://www.researchgate.net/publication/356387273/figure/fig2/AS:1094515989458945@1637964355312/Correlations-of-TILs-with-multiplex-IHC-a-Correlation-matrix-of-the-different-variables_Q320.jpg)
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
![Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer](https://www.mdpi.com/cancers/cancers-11-01479/article_deploy/html/images/cancers-11-01479-g004-550.jpg)
Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
![Tumor-infiltrating lymphocytes and the PD-L1/PD-1 signaling axis in breast cancer: biology and clinical implications | Semantic Scholar Tumor-infiltrating lymphocytes and the PD-L1/PD-1 signaling axis in breast cancer: biology and clinical implications | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/472ccf8bfee0c40f358a970f256f84553441069f/20-Figure1-1.png)
Tumor-infiltrating lymphocytes and the PD-L1/PD-1 signaling axis in breast cancer: biology and clinical implications | Semantic Scholar
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
![Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer](https://www.mdpi.com/cancers/cancers-11-01479/article_deploy/html/images/cancers-11-01479-g001.png)
Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
![Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology](https://www.researchgate.net/profile/Emmanouil-Sifakis/publication/341640726/figure/fig3/AS:967485306187777@1607677880132/Forest-plot-for-overall-survival-according-to-programmed-cell-death-protein-1-PD-1_Q320.jpg)
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn
![Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology](https://www.researchgate.net/profile/Emmanouil-Sifakis/publication/341640726/figure/fig2/AS:967485306200065@1607677880096/Flow-chart-of-search-and-study-selection-in-the-meta-analysis-of-studies-evaluating_Q320.jpg)
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
![Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology](https://www.researchgate.net/publication/356387273/figure/fig1/AS:1094515989446656@1637964355196/TILs-manual-and-digital-evaluation-Representative-image-of-a-tissue-microarray-TMA_Q320.jpg)
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology
![Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology](https://www.researchgate.net/publication/356387273/figure/fig3/AS:1094515989450752@1637964355339/Combined-immunogenomic-analysis-in-the-SBG-2004-1-trial-a-b-CNA-clusters-and-graph_Q320.jpg)